AAV yield, bioactivity, and particle heterogeneity are impacted by genome size and non-coding DNA elements
Open Access
- 2 June 2025
- journal article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 33 (3) , 101499
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 38 references indexed in Scilit:
- Evaluation of the loading capacity and patterns of packaged DNA in AAV genomes of different sizes using long-read sequencingMolecular Therapy - Methods & Clinical Development, 2025
- Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cellsMolecular Therapy - Methods & Clinical Development, 2024
- Recombinant AAV genome size effect on viral vector production, purification, and thermostabilityMolecular Therapy - Methods & Clinical Development, 2024
- Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standardMolecular Therapy - Methods & Clinical Development, 2023
- Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analysesMolecular Therapy - Methods & Clinical Development, 2022
- Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systemsNeuron, 2022
- Quantitative analysis of genome packaging in recombinant AAV vectors by charge detection mass spectrometryMolecular Therapy - Methods & Clinical Development, 2021
- Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2Molecular Therapy - Methods & Clinical Development, 2019
- Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector ChimerasMolecular Therapy - Methods & Clinical Development, 2018
- A Robust System for Production of Superabundant VP1 Recombinant AAV VectorsMolecular Therapy - Methods & Clinical Development, 2017